Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanofi

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SANOFI'S QFITLIA AND CABLIVI APPROVED IN CHINA, EXPANDING CARE FOR RARE DISEASES QFITLIA, THE FIRST ANTITHROMBIN-LOWERING THERAPY FOR HEMOPHILIA, CAN OFFER CONSISTENT PROTECTION WITH AS FEW AS SIX INJECTIONS A YEAR CABLIVI, THE FIRST NANOBODY MEDICINE, TARGETS ACQUIRED/IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA  A RARE, LIFE-THREATENING BLOOD CLOTTING DISORDER PARIS, DECEMBER 11, 2025. THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA HAS APPROVED TWO INNOVATIVE SANOFI MEDICINES FOR RARE HEMATOLOGIC DISEASES: QFITLIA (FITUSIRAN) FOR HEMOPHILIA AND CABLIVI (CAPLACIZUMAB) FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA.

PRESS RELEASE: SANOFI'S QFITLIA AND CABLIVI APPROVED IN CHINA, EXPANDING CARE FOR RARE DISEASES

SEATTLE & CAMBRIDGE, MASS.--(BUSINESS WIRE)--INDUPRO, INC., A BIOTECHNOLOGY COMPANY DEFINING MEMBRANE PROTEIN SPATIAL RELATIONSHIPS TO CREATE NOVEL THERAPEUTICS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED A STRATEGIC EQUITY INVESTMENT AND RESEARCH COLLABORATION WITH SANOFI. THE AGREEMENT WITH SANOFI INCLUDES THE RIGHT OF FIRST NEGOTIATION FOR INDUPRO'S BISPECIFIC PD-1 AGONIST PROGRAM, WHICH IS CURRENTLY IN PRECLINICAL DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE AND INFL.

INDUPRO THERAPEUTICS ANNOUNCES STRATEGIC INVESTMENT FROM SANOFI AND A RESEARCH COLLABORATION TO ADVANCE A NOVEL BISPECIFIC FOR AUTOIMMUNE DISORDERS

SANOFI COMPLETES ACQUISITION OF VICEBIO PARIS, DECEMBER 4, 2025. SANOFI ANNOUNCES THE COMPLETION OF ITS ACQUISITION OF VICEBIO LTD (VICEBIO).

PRESS RELEASE: SANOFI COMPLETES ACQUISITION OF VICEBIO

LONDON--(BUSINESS WIRE)-- #AI--LABGENIUS THERAPEUTICS (LABGENIUS), A DRUG DISCOVERY COMPANY COMBINING MACHINE LEARNING (ML) AND HIGH-THROUGHPUT EXPERIMENTATION TO OPTIMISE POTENTIAL THERAPEUTIC ANTIBODIES, TODAY ANNOUNCED A SECOND COLLABORATION WITH SANOFI. THIS COLLABORATION COMBINES LABGENIUS' AI/ML-DRIVEN ANTIBODY DESIGN CAPABILITIES WITH SANOFI'S EXPERTISE IN THE DEVELOPMENT OF THERAPEUTIC NANOBODY MOLECULES TO CO-OPTIMISE PROTEINS FOR THERAPEUTICALLY VALUABLE PROPERTIES. FOLLOWING THE SUCCESS.

LABGENIUS THERAPEUTICS ANNOUNCES NEW COLLABORATION WITH SANOFI FOR MULTIPLE AI/ML-DRIVEN ANTIBODY OPTIMISATION PROGRAMMES

SANOFI AND REGENERON'S DUPIXENT APPROVED AS THE FIRST TARGETED MEDICINE IN THE EU IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA

PRESS RELEASE: SANOFI AND REGENERON'S DUPIXENT APPROVED AS THE FIRST TARGETED MEDICINE IN THE EU IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA

BURLINGTON, MASSACHUSETTS--(NEWSFILE CORP. - NOVEMBER 18, 2025) - LIFORDI IMMUNOTHERAPEUTICS, INC., A CLINICAL-STAGE BIOTECH COMPANY DEVELOPING ANTIBODY-DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS, TODAY ANNOUNCED A STRATEGIC INVESTMENT FROM SANOFI VENTURES, THE VENTURE ARM OF GLOBAL HEALTHCARE LEADER SANOFI, AND FUNDING FROM EXISTING INVESTORS ARCH VENTURES, 5AM VENTURES, AND ATLAS VENTURE. THE NEW FUNDS BRING THE TOTAL RAISED TO $112 MILLION AND SUPPORT AN ONGOING PHASE 1 STUDY IN RHEUMATOID ARTHRITIS (RA) DESIGNED TO EVALUATE LFD-200, AN ADC DELIVERING A POTENT GLUCOCORTICOID (GC) DIRECTLY TO IMMUNE CELLS.

LIFORDI IMMUNOTHERAPEUTICS SECURES STRATEGIC INVESTMENT FROM SANOFI VENTURES AND ADDITIONAL CAPITAL FROM EXISTING INVESTORS

BURLINGTON, MASS.--(BUSINESS WIRE)-- #ADCS--LIFORDI IMMUNOTHERAPEUTICS, INC., A CLINICAL-STAGE BIOTECH COMPANY DEVELOPING ANTIBODY-DRUG CONJUGATES (ADCS) FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS, TODAY ANNOUNCED A STRATEGIC INVESTMENT FROM SANOFI VENTURES, THE VENTURE ARM OF GLOBAL HEALTHCARE LEADER SANOFI, AND FUNDING FROM EXISTING INVESTORS ARCH VENTURES, 5AM VENTURES, AND ATLAS VENTURE. THE NEW FUNDS BRING THE TOTAL RAISED TO $112 MILLION AND SUPPORT AN ONGOING PHASE 1 STUDY IN RHE.

SANOFI'S TEIZEILD RECOMMENDED FOR EU APPROVAL BY THE CHMP FOR PATIENTS WITH STAGE 2 TYPE 1 DIABETES RECOMMENDATION BASED ON THE TN-10 STUDY, DEMONSTRATING TEIZEILD'S ABILITY TO DELAY THE ONSET OF STAGE 3 TYPE 1 DIABETES (T1D), COMPARED TO PLACEBO, IN ADULTS AND CHILDREN WITH STAGE 2 T1D IF APPROVED, TEIZEILD WOULD BECOME THE FIRST DISEASE-MODIFYING T1D THERAPY IN THE EU PARIS, NOVEMBER 14, 2025. THE EUROPEAN MEDICINES AGENCY (EMA)'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF TEIZEILD (TEPLIZUMAB) TO DELAY THE ONSET OF STAGE 3 T1D IN ADULT AND PEDIATRIC PATIENTS EIGHT YEARS OF AGE AND OLDER WITH STAGE 2 T1D.

PRESS RELEASE: SANOFI'S TEIZEILD RECOMMENDED FOR EU APPROVAL BY THE CHMP FOR PATIENTS WITH STAGE 2 TYPE 1 DIABETES

ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW

PRESS RELEASE: ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW

MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

UPDATE: DASSAULT SYSTMES: MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES WITH THE GOAL OF STREAMLINING CLINICAL PROCESSES AND DATA, ENHANCING PATIENT CARE EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES WITH THE GOAL OF STREAMLINING CLINICAL PROCESSES AND DATA, ENHANCING PATIENT CARE

UPDATE - MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

Q3: CONTINUED SALES AND EARNINGS PROGRESS PARIS, OCTOBER 24, 2025 Q3 SALES GROWTH OF 7.0% AT CER1 AND BUSINESS EARNINGS PER SHARE (EPS)2 OF 2.91 PHARMA LAUNCHES INCREASED SALES BY 57.1%, REACHING 1.0 BILLION, DRIVEN BY ALTUVIIIO AND AYVAKIT DUPIXENT SALES INCREASED BY 26.2% TO 4.2 BILLION, FIRST TIME ABOVE 4 BILLION IN A QUARTER VACCINES SALES DECREASED BY 7.8% TO 3.4 BILLION, FROM LOWER INFLUENZA SALES RESEARCH AND DEVELOPMENT EXPENSES WERE 1.8 BILLION, AN INCREASE OF 4.9% SELLING, GENERAL AND ADMINISTRATIVE EXPENSES WERE 2.3 BILLION, UP 7.1% TO SUPPORT LAUNCHES BUSINESS EPS WAS 2.91, UP 13.2% AT CER AND 7.0% AT ACTUAL EXCHANGE RATES, DELIVERING PROFITABLE GROWTH; IFRS EPS WAS 2.30 PIPELINE PROGRESS TWO REGULATORY APPROVALS: WAYRILZ (US) IN ITP, A RARE DISEASE, AND TZIELD (CHINA) FOR DELAYING ONSET OF STAGE 3, TYPE 1 DIABETES TWO POSITIVE PHASE 3 READOUTS: AMLITELIMAB'S FIRST PHASE 3 STUDY IN ATOPIC DERMATITIS AND FLUZONE HD IN INFLUENZA 50+ YEARS EIGHT REGULATORY SUBMISSION ACCEPTANCES, THREE PHASE 3 STUDY STARTS, AND THREE REGULATORY DESIGNATIONS (FAST TRACK, ORPHAN) CAPITAL ALLOCATION COMPLETION OF THE VIGIL NEUROSCIENCE ACQUISITION, ADDING TO THE EARLY-STAGE PIPELINE ADDITIONAL COMMITMENT OF $625 MILLION TO SANOFI VENTURES, INVESTING IN INNOVATIVE BIOTECH AND DIGITAL HEALTH COMPANIES SANOFI INTENDS TO COMPLETE ITS 5 BILLION SHARE BUYBACK PROGRAM IN 2025. 86.1% HAS BEEN EXECUTED TO DATE SUSTAINABILITY GLOBAL HEALTH UNIT: ONE MILLION PATIENTS HAVE NOW RECEIVED TREATMENTS FOR NON-COMMUNICABLE DISEASES SINCE 2021 INSULINS VALYOU SAVINGS PROGRAM: IMPROVING ACCESS TO RELIABLE AND AFFORDABLE SUPPLY OF CRITICAL MEDICINES IN THE US GUIDANCE UNCHANGED IN 2025, SALES ARE ANTICIPATED TO GROW BY A HIGH SINGLE-DIGIT PERCENTAGE AT CER.

PRESS RELEASE: Q3: CONTINUED SALES AND EARNINGS PROGRESS

EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES, ENABLING SANOFI TO STREAMLINE OPERATIONS, REFINE DATA QUALITY, AND ENHANCE PATIENT CARE EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES, ENABLING SANOFI TO STREAMLINE OPERATIONS, REFINE DATA QUALITY, AND ENHANCE PATIENT CARE

SANOFI DEEPENS PARTNERSHIP WITH MEDIDATA TO EXPEDITE THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

DASSAULT SYSTMES: SANOFI DEEPENS PARTNERSHIP WITH MEDIDATA TO EXPEDITE THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

SANOFI'S EFDORALPRIN ALFA MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN ALPHA-1 ANTITRYPSIN DEFICIENCY EMPHYSEMA PHASE 2 STUDY

PRESS RELEASE: SANOFI'S EFDORALPRIN ALFA MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN ALPHA-1 ANTITRYPSIN DEFICIENCY EMPHYSEMA PHASE 2 STUDY

SANOFI'S TZIELD ACCEPTED FOR EXPEDITED REVIEW IN THE US FOR STAGE 3 TYPE 1 DIABETES THROUGH FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAM

PRESS RELEASE: SANOFI'S TZIELD ACCEPTED FOR EXPEDITED REVIEW IN THE US FOR STAGE 3 TYPE 1 DIABETES THROUGH FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAM

ESMO: ALPHAMEDIX TM PHASE 2 DATA SUPPORT FIRST-IN-CLASS POTENTIAL OF NEW TARGETED ALPHA THERAPY IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS NEW ALPHAMEDIX DATA SHOWED SUSTAINED AND CLINICALLY MEANINGFUL RESPONSES ACROSS BOTH RLT-NAVE AND RLT-EXPOSED PATIENTS WITH UNRESECTABLE OR METASTATIC GEP-NETS FIRST PHASE 2 STUDY TO EVALUATE TAT WITH LEAD-212 SUPPORTING ITS POTENTIAL TO ADDRESS HIGH UNMET MEDICAL NEEDS IN DIFFICULT-TO-TREAT, RARE CANCERS PHASE 2 STUDY MET ALL PRIMARY EFFICACY ENDPOINTS AND WAS PRESENTED ACROSS TWO ORAL PRESENTATIONS AT THE 2025 ESMO CONGRESS IN BERLIN, GERMANY PARIS, OCTOBER 20, 2025.NEW DATA FROM THE ALPHAMEDIX-02 PHASE 2 STUDY (CLINICAL STUDY IDENTIFIER: NCT05153772) EVALUATING ALPHAMEDIX (212PB-DOTAMTATE), AN INVESTIGATIONAL SOMATOSTATIN RECEPTOR (SSTR) TARGETED ALPHA THERAPY (TAT) USING THE LEAD-212 ISOTOPE, UNDERSCORE THE FIRST-IN-CLASS POTENTIAL OF THIS INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS).

PRESS RELEASE: ESMO: ALPHAMEDIXTM PHASE 2 DATA SUPPORT FIRST-IN-CLASS POTENTIAL OF NEW TARGETED ALPHA THERAPY IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

SANOFI'S HIGH-DOSE INFLUENZA VACCINE DEMONSTRATES SUPERIOR PROTECTION FOR OLDER ADULTS AGAINST HOSPITALIZATION VS STANDARD-DOSE

PRESS RELEASE: SANOFI'S HIGH-DOSE INFLUENZA VACCINE DEMONSTRATES SUPERIOR PROTECTION FOR OLDER ADULTS AGAINST HOSPITALIZATION VS STANDARD-DOSE

SANOFI'S WAYRILZ RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT IMMUNE THROMBOCYTOPENIA RECOMMENDATION BASED ON LUNA 3 PHASE 3 STUDY DEMONSTRATING RAPID AND DURABLE PLATELET RESPONSE AND SIGNIFICANT IMPROVEMENTS IN BLEEDING, QUALITY OF LIFE MEASURES, AND OTHER ITP SYMPTOMS IF APPROVED, WAYRILZ WILL BE THE FIRST BTK INHIBITOR FOR ITP IN THE EU, TARGETING THE ROOT CAUSE OF THE DISEASE THROUGH MULTI-IMMUNE MODULATION PARIS, OCTOBER 17, 2025. THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF WAYRILZ (RILZABRUTINIB) AS A NEW TREATMENT FOR IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS.

PRESS RELEASE: SANOFI'S WAYRILZ RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT IMMUNE THROMBOCYTOPENIA

SANOFI PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR REZUROCK TO TREAT CHRONIC GRAFT-VS-HOST DISEASE PARIS, OCTOBER 17, 2025. THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ISSUED A NEGATIVE OPINION ON THE MARKETING AUTHORISATION APPLICATION FOR REZUROCK (BELUMOSUDIL) FOR THE THIRD-LINE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD).

PRESS RELEASE: SANOFI PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR REZUROCK TO TREAT CHRONIC GRAFT-VS-HOST DISEASE

CHICAGO , OCT. 16, 2025 /PRNEWSWIRE/ -- EVOQ THERAPEUTICS, INC. (EVOQ), A BIOTECHNOLOGY COMPANYFOCUSED ON DELIVERING TRANSFORMATIVE CURES FOR THOSE LIVING WITH AUTOIMMUNE DISEASES, TODAYANNOUNCED A COLLABORATION AND LICENSE AGREEMENT WITH SANOFI, AN R&D DRIVEN, AI-POWEREDBIOPHARMA COMPANY, COMMITTED TO IMPROVING PEOPLE'S LIVES AND DELIVERING COMPELLING GROWTH. SANOFI IS LISTED ON EURONEXT: SAN AND NASDAQ: SNY EVOQ'S PROPRIETARY BREAKTHROUGH NANODISC TECHNOLOGY RESTORES THE BODY'S NATURAL IMMUNETOLERANCE PATHWAYS AND OPENS THE DOOR FOR A WIDE RANGE OF DISEASE-SPECIFIC, CURATIVE THERAPIESFOR MULTIPLE AUTOIMMUNE DISEASES LIKE CELIAC DISEASE, TYPE 1 DIABETES, MOG (MYELINOLIGODENDROCYTE GLYCOPROTEIN) ANTIBODY DISEASE, RHEUMATOID ARTHRITIS AND LUPUS.

EVOQ THERAPEUTICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH SANOFI

GARCHING / MUNICH, GERMANY, OCTOBER 13, 2025  ITM ISOTOPE TECHNOLOGIES MUNICH SE (ITM), A LEADING RADIOPHARMACEUTICAL BIOTECH COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF ANNETTE BREUNIG AS CHIEF PEOPLE OFFICER (CPO). MS. BREUNIG BRINGS OVER 25 YEARS OF HR LEADERSHIP EXPERIENCE AT INTERNATIONAL PHARMACEUTICAL, MANUFACTURING AND TECHNOLOGY COMPANIES, INCLUDING AT SIEMENS AG (FRA: SIE) AND SANOFI (NASDAQ: SNY). AT ITM, MS. BREUNIG WILL LEAD THE HR TEAM IN SHAPING STRATEGIES THAT UNIFY THE ORGANIZATION TO ACHIEVE BOTH TEAM AND BUSINESS GROWTH OBJECTIVES WHILE EMPOWERING EMPLOYEES, STRENGTHENING COMPANY CULTURE AND ATTRACTING TOP TALENT. ANNETTE'S DEDICATION TO SUPPORTING TOP-PERFORMING TEAMS AT GLOBAL, HIGH-GROWTH COMPANIES HAS CREATED DYNAMIC WORK ENVIRONMENTS. AS ITM CONTINUES SCALING ITS ORGANIZATION TO MEET THE NEEDS OF PEOPLE LIVING WITH CANCER, HER LEADERSHIP WILL BE A GREAT ADDITION, SAID DR. ANDREW CAVEY, CEO OF ITM. OUR PEOPLE ARE THE CORE THAT DRIVE OUR SUCCESS. THIS APPOINTMENT FURTHER STRENGTHENS OUR HR TEAM'S ABILITY TO ELEVATE EMPLOYEES AND ENSURES THAT ITM REMAINS A GREAT PLACE TO WORK AS WE ADVANCE OUR MISSION TO DEVELOP INNOVATIVE RADIOPHARMACEUTICALS . AS EXECUTIVE VICE PRESIDENT OF PEOPLE & CULTURE AT INFIOS GROUP (FORMERLY KRBER SUPPLY CHAIN SOFTWARE), ANNETTE LED THE INTEGRATION OF THE COMPANY'S WORKFORCE ACROSS 10 COUNTRIES IN ASIA, EUROPE, AND THE UNITED STATES INTO A COHESIVE AND UNIFIED GLOBAL CULTURE. AS VICE PRESIDENT OF HR AT KRBER SUPPLY CHAIN GROUP AND AT KRBER PHARMA SHE ESTABLISHED GLOBAL HR TEAMS, DEVELOPED AND IMPLEMENTED THE COMPANIES' GLOBAL PEOPLE STRATEGIES, AND LAUNCHED MAJOR GLOBAL CULTURE INITIATIVES. ANNETTE ALSO HELD GLOBAL SENIOR LEADERSHIP AND MANAGEMENT ROLES FOR MORE THAN TEN YEARS AT SIEMENS AG, WHERE SHE OVERSAW STRATEGIC AND OPERATIONAL HR FUNCTIONS, INCLUDING THE DEVELOPMENT OF SYSTEMS FOR HIRING AND DEVELOPING BEST-IN-CLASS TALENT, AND THE DESIGNED COMPENSATION STRATEGIES AND POLICIES. SHE ALSO WORKED IN SENIOR MANAGEM

ITM APPOINTS ANNETTE BREUNIG AS CHIEF PEOPLE OFFICER

TORONTO--(BUSINESS WIRE)--BENCHSCI ANNOUNCES THREE-YEAR LICENSE AGREEMENT WITH SANOFI TO ACCESS AND USE BENCHSCI'S ASCEND PLATFORM.

BENCHSCI ANNOUNCES THREE-YEAR LICENSE AGREEMENT WITH SANOFI TO ACCESS AND USE BENCHSCI'S ASCEND PLATFORM

ALPHAMEDIX TM ( 212 PB-DOTAMTATE) ACHIEVED ALL PRIMARY EFFICACY ENDPOINTS IN PHASE 2 STUDY, DEMONSTRATING CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

PRESS RELEASE: ALPHAMEDIXTM (212PB-DOTAMTATE) ACHIEVED ALL PRIMARY EFFICACY ENDPOINTS IN PHASE 2 STUDY, DEMONSTRATING CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

Sanofi

SNY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Sanofi

SNY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SNY